Eisai and Biogen (BIIB) have received U.S. FDA approval for LEQEMBI IQLIK, a once weekly subcutaneous autoinjector initiation dose for early Alzheimer’s. This enables at home treatment and offers an alternative to intravenous infusions.

Biogen’s share price has recently picked up, with a 1-day share price return of 4.96% and a 90-day share price return of 16.80%. The 1-year total shareholder return of 57.04% contrasts with weaker 3 and 5 year total shareholder returns, suggesting momentum has strengthened only in the more recent period.

If this Alzheimer’s progress has your attention, it could be a good moment to look across the wider healthcare technology space using our screener for 40 healthcare AI stocks

Biogen’s recent share price jump sits at the crossroads of changing expectations and the underlying Alzheimer’s franchise story. To see which side is doing more of the work, it helps to line up the current valuation next.

Most Popular Narrative: 4.7% Undervalued

The most followed valuation narrative currently places Biogen’s fair value at about $219, modestly above the last close of $209.03 and framing the latest Alzheimer’s news within a slightly supportive valuation gap.

Broad international rollout and expanding reimbursement for SKYCLARYS and ZURZUVAE, particularly in rare diseases and underpenetrated markets, leverages growing global healthcare spending and improvements in medical infrastructure worldwide, increasing access and boosting long-term topline growth.

Curious what underpins that fair value for Biogen? The narrative leans on steady revenue expansion, rising profit margins, and a future earnings multiple that assumes meaningful earnings growth. The full story ties those inputs directly to specific product launches and long term forecasts.

Result: Fair Value of $219.27 (UNDERVALUED)

However, Biogen’s story still leans heavily on a small group of new launches, and rising biosimilar and pricing pressure could challenge the current Alzheimer’s driven optimism.

Another View: Biogen Through the P/E Lens

While the current fair value narrative suggests Biogen is modestly undervalued, the P/E picture is less forgiving. The stock trades on about 22.5x earnings, above both the US Biotechs average of 17.4x and peers at 18.8x, although close to its fair ratio of 23.5x.

This mix of a premium relative to the sector and alignment with the fair ratio points to limited room for error in the Biogen story, especially if earnings or drug launches fall short of expectations. For investors comparing price and fundamentals, how comfortable does that valuation buffer really feel today? See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment around Biogen looking more optimistic but not one sided, it makes sense to review the underlying data yourself and move quickly to form a view based on the balance of risks and rewards. To see that balance set out clearly, take a closer look at the 2 key rewards and 1 important warning sign

Looking for more ideas beyond Biogen?

If Biogen has sharpened your focus on healthcare, do not stop there. Widen your watchlist with other stocks that fit clear, disciplined criteria.

• Spot potential bargains early by scanning for companies that combine quality fundamentals with attractive pricing using the 46 high quality undervalued stocks
• Build a sturdier core to your portfolio by filtering for companies with stronger financial footing through the solid balance sheet and fundamentals stocks screener (47 results)
• Hunt for underfollowed opportunities by checking a screener containing 20 high quality undiscovered gems before the crowd catches on

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.